Ratiopharm GmbH has attracted at least 10 first-round bids, several people familiar with the procedure told Reuters. The sources said that bidders include Teva Pharmaceutical Industries Limited, Mylan, Inc., Sanofi-Aventis, Sinopharm Group Co. Ltd. and Actavis Group Hf. Firms participating in the round of bids, which were non-binding, include TPG, Advent International Corporation in collaboration with Goldman Sachs Private Equity Group, Permira Advisers Ltd. and Kohlberg Kravis Roberts & Co. (KKR). One source said EQT Partners AB had also filed a bid. Some of the sources said that bidders will be asked to confirm their non-binding offers in December and a smaller group will make binding offers in February. Ratiopharm has said it aims to conclude a deal in the first quarter of 2010. Reuters reported that a spokesman for Ratiopharm declined to comment. It added that Teva, Actavis, Goldman Sachs Private Equity Group, Permira and KKR also declined comment. Reuters reported that Sanofi, Sinopharm and Mylan were not immediately available for comment. Earlier this month, Teva�s President and Chief Executive, Shlomo Yanai declined to comment on Ratiopharm but said Teva was "scrutinising the industry constantly looking for acquisitions" that would be accretive to its earnings in the first year. Several sources close to the proceedings also told Reuters on Wednesday that most bids came in between �2 billion and �2.5 billion. A spokesman for Vem Verm�gensverwaltung Gmbh (VEM), said last week that VEM was positively surprised by the number of bids and that it was "very satisfied" with the level of the offers. Encouraged by the interest from suitors, the sale of Ratiopharm as a whole remained a priority, he said at the time. Commerzbank and Royal Bank of Scotland are managing the sale.

Mylan Inc. expects to be the first company to sell a generic version of Pfizer's antifungal drug Vfend after reaching a settlement and licensing agreement with the company. The agreement will give Mylan the right to market 50-and 200-mg tablets of generic Vfend (voriconazole) in the first quarter of 2011, and the company is likely to have 180 days of marketing exclusivity.

Mylan Inc. reported unaudited consolidated earnings results for the nine months ended September 30, 2009. Total revenues for the nine months ended September 30, 2009 were $3.74 billion compared to $3.93 billion for the same prior year period. Included in total revenues were other revenues of $61.1 million in the current year compared to $493.8 million in the same prior year period. The prior year includes $468.1 million related to the sale of Bystolic. Excluding this, other revenue increased by $35.5 million, primarily the result of approximately $26.0 million of incremental revenue resulting from the cancellation of certain product development agreements. Net revenues were $3.68 billion compared to $3.44 billion in the same prior year period, an increase of $239.2 million or 7.0%. On a constant currency basis, year-over-year revenue growth would have been approximately 14%. Earnings from operations were $463.3 million compared to earnings from operations of $263.3 million for the nine months ended September 30, 2008. Excluding items, as well as the impact of the Bystolic revenue in 2008 and the purchase accounting related items in both periods, as mentioned above, earnings from operations were $785.1 million compared to $515.9 million for the prior year, an increase of 52.2%. This increase in operating income in the current year is due to increased revenue and gross profit, as well as lower overall operating expenses, which decreased as a result of the favorable effect of the stronger U.S. dollar and by synergies realized as a result of the company's ongoing restructuring initiatives. EBITDA was $791.1 million. After adjusting for certain non-recurring or non-cash items as further discussed below, adjusted EBITDA was $942.1 million. The company reported earnings before income taxes and non controlling interest of $252.86 million, net earnings attributable to the non controlling interest of $200.32 million, net earnings attributable to the company before preferred dividends of $193.66 million and net earnings attributable to the company of $89.39 million or $0.29 per diluted share compared to earnings before income taxes and non controlling interest of $1.47 million, net loss attributable to the non controlling interest of $178.59 million, net loss attributable to the company before preferred dividends of $176.32 million and net loss attributable to the company of $280.56 million or $0.92 per diluted share for the same period a year ago. On adjusted basis, the company reported earnings from operations of $838.6 million, earnings before income taxes and non controlling interest of $634.1 million, net earnings of $443.9 million, net earnings attributable to the company before preferred dividends and net earnings attributable to the company of $440.2 million or $0.97 per share. Cash provided by operating activities was $546.6 million. Capital expenditures were $83.1 million.